WellsSAJr, AsaSL, DralleH, EliseiR, EvansDB, GagelRF, LeeNY, MachensA, MoleyJF, PaciniF, RaueF, Frank-RaueK, RobinsonB, RosenthalMS, SantoroM, SchlumbergerM, ShahM, WaguespackSG. 2015. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma The American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Thyroid, 25:567–610.
2.
ErlicZ, HoffmannMM, SullivanM, FrankeG, PeczkowskaM, HarschI, SchottM, GabbertHE, ValimäkiM, PreussSF, Hasse-LazarK, WaligorskiD, RobledoM, JanuszewiczA, EngC, NeumannHP. 2010. Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome. J Clin Endocrinol Metab, 95:308–313.
3.
PęczkowskaM, KowalskaA, SygutJ, WaligórskiD, MalinocA, Janaszek-SitkowskaH, PrejbiszA, JanuszewiczA, NeumannHP. 2013. Testing new susceptibility genes in the cohort of apparently sporadic phaeochromocytoma/paraganglioma patients with clinical characteristics of hereditary syndromes. Clin Endocrinol, 79:817–823.
4.
ToledoRA, HatakanaR, LourençoDMJr, LindseySC, CamachoCP, AlmeidaM, LimaJVJr, SekiyaT, GarraldaE, NaslavskyMS, YamamotoGL, LazarM, MeirellesO, SobreiraTJ, LebraoML, DuarteYA, BlangeroJ, ZatzM, CeruttiJM, MacielRM, ToledoSP. 2015. Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility. Endocr Relat Cancer, 22:65–76.
